Literature DB >> 12530979

Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I.

Eric Reits1, Alexander Griekspoor, Joost Neijssen, Tom Groothuis, Kees Jalink, Peter van Veelen, Hans Janssen, Jero Calafat, Jan Wouter Drijfhout, Jacques Neefjes.   

Abstract

Antigenic peptides generated by the proteasome have to survive a peptidase-containing environment for presentation by MHC class I molecules. We have visualized the fate and dynamics of intracellular peptides in living cells. We show that peptides are distributed over two different but interconnected compartments, the cytoplasm and the nucleus, and diffuse rapidly through and between these compartments. Since TAP is excluded from the nuclear face of the nuclear envelope, nuclear peptides have to leave the nucleus to contact TAP. Thereby, these peptides encounter cytosolic peptidases that degrade peptides within seconds unless bound to chromatin. Since peptide degradation is far more efficient than translocation, many peptides will be lost for antigen presentation by MHC class I molecules.

Mesh:

Substances:

Year:  2003        PMID: 12530979     DOI: 10.1016/s1074-7613(02)00511-3

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  97 in total

Review 1.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

Review 2.  DRiPs solidify: progress in understanding endogenous MHC class I antigen processing.

Authors:  Jonathan W Yewdell
Journal:  Trends Immunol       Date:  2011-09-29       Impact factor: 16.687

3.  Quantitative aspects of intracellularly-targeted drug delivery.

Authors:  David Stepensky
Journal:  Pharm Res       Date:  2010-09-02       Impact factor: 4.200

Review 4.  Fishing for the hidden peptidome in health and disease (drug abuse).

Authors:  Lloyd D Fricker; Jonathan V Sweedler
Journal:  AAPS J       Date:  2010-09-18       Impact factor: 4.009

5.  Mining the plasma immunopeptidome for cancer peptides as biomarkers and beyond.

Authors:  Heather D Hickman; Jonathan W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

6.  Peptidomic analysis of HEK293T cells: effect of the proteasome inhibitor epoxomicin on intracellular peptides.

Authors:  Lloyd D Fricker; Julia S Gelman; Leandro M Castro; Fabio C Gozzo; Emer S Ferro
Journal:  J Proteome Res       Date:  2012-02-16       Impact factor: 4.466

7.  Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules.

Authors:  Celia R Berkers; Annemieke de Jong; Karianne G Schuurman; Carsten Linnemann; Hugo D Meiring; Lennert Janssen; Jacques J Neefjes; Ton N M Schumacher; Boris Rodenko; Huib Ovaa
Journal:  J Immunol       Date:  2015-09-23       Impact factor: 5.422

8.  The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage.

Authors:  Morten Nielsen; Claus Lundegaard; Ole Lund; Can Keşmir
Journal:  Immunogenetics       Date:  2005-03-03       Impact factor: 2.846

9.  Peptidases released by necrotic cells control CD8+ T cell cross-priming.

Authors:  Jaba Gamrekelashvili; Tamar Kapanadze; Miaojun Han; Josef Wissing; Chi Ma; Lothar Jaensch; Michael P Manns; Todd Armstrong; Elizabeth Jaffee; Ayla O White; Deborah E Citrin; Firouzeh Korangy; Tim F Greten
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

10.  An in silico model of cytotoxic T-lymphocyte activation in the lymph node following short peptide vaccination.

Authors:  Liam V Brown; Eamonn A Gaffney; Jonathan Wagg; Mark C Coles
Journal:  J R Soc Interface       Date:  2018-03       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.